Second dose inoculation for 15-18 age group to begin in MP on Monday

 Administration of the second dose of anti-Covid-19 vaccines to eligible children in the 15-18 age group will begin from Monday in Madhya Pradesh, an official said

Administration of the second dose of anti-COVID-19 vaccines to eligible children in the 15-18 age group will begin from Monday in Madhya Pradesh, an official said on Sunday. Letters were written to all the district collectors in MP in this regard, National Health Mission director Priyanka Das said in an official statement. All the eligible persons from the 15-18 age group will be given the second dose of COVID-19 vaccines from Monday, it said.

Das said 36.42 lakh eligible children from this age group had received the first dose of vaccines against the target of 48 lakh. She said that sessions for the second jab for the eligible teens will be organised in the schools, where the first dose was administered. Das said that registration for the second dose will be held on the spot.

Pokhriyal launches world's most affordable Covid-19 diagnostic kit by IIT-D

HRD Minister Ramesh Pokhriyal virtually launched the world’s most affordable RT-PCR-based Covid-19 diagnostic kit ‘Corosure’ developed by IIT Delhi, and approved by the ICMR and DCGI

Union Human Resource Development (HRD) Minister Ramesh Pokhriyal on Wednesday virtually launched the world’s most affordable RT-PCR based COVID-19 diagnostic kit “Corosure” developed by IIT Delhi, and approved by the ICMR and DCGI.

Speaking on the occasion, the minister said that “Corosure”– COVID-19 Diagnostic Kit developed by IIT Delhi is a step towards Prime Minister Narendra Modi’s vision of a self-reliant India, read a release. He said that the country requires cheap and reliable testing which can help to control the pandemic.

“The Corosure Kit has been developed indigenously and is much cheaper than other kits. Our Prime Minister has always been encouraging the youth of the country to come forward and ensure a healthier India especially in the times of COVID 19 pandemic with their innovative research. The kit has received ICMR approval with the highest score and DCGI approved with a very high sensitivity and specificity,” Pokhriyal said…Read More

Clinical trial begins to assess plasma efficacy to limit Covid-19: ICMR

Convalescent plasma is one of several emerging therapies. However, there is no robust evidence to support it for routine therapy

The Indian Council of Medical Research has started a multi-centre clinical trial to assess the safety of the convalescent plasma to limit any coronavirus related complications. “ICMR has initiated a multi-centre clinical trial to assess the safety and efficacy of convalescent plasma to limit Covid-19 associated complications in moderate disease,” read an official statement by the ICMR. The trial has been titled as “A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit Covid-19 Associated Complications in Moderate Disease.”

ALSO READ: Coronavirus LIVE: India cases rise to 52,987; Maharashtra tally at 16,758

On April 28, the ICMR had said that currently there are no approved, definitive therapies for Covid-19. Convalescent plasma is one of several emerging therapies. However, there is no robust evidence to support it for routine therapy, the research body said. Meanwhile, the total number of coronavirus cases in the country has reached 49,391, including 14,183 recovered/migrated and 1,694 deaths, as per the Union Ministry of Health and Family Welfare…